Share this video  

ASCO 2021 | The rapid growth of FGFR2 inhibitors: pemigatinib in FIGHT-202

Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany talks on the FIGHT-202 trial (NCT02924376) which is evaluating the efficacy of pemigatinib in patients with advanced or surgically unresectable cholangiocarcinoma. The efficacy data of pemigatinib showed a response rate of 37%; median overall progression-free survival was less than 30 months, leading to its approval by FDA and EMA. Prof. Vogel mentions the increasing number of trials with other FGFR2 inhibitors as the efficacy of this class of drugs continues to grow. This interview took place at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021.


Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.